You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信下調中生製藥(01177.HK)目標價至8元 評級「跑贏大市」
阿思達克 04-04 09:52
瑞信發表報告指,中生製藥(01177.HK)去年收入符預期,疫苗收入勝該行預期。但不含疫苗的利潤按年下降65%。該行指,中生製藥在2022年至2024年將有大約10個創新藥物獲批,預計今年新冠疫苗收入將減少。 瑞信指,根據去年表現和指引,將中生製藥2022和2023財年的收入分別下調2%和5%,並調整2022和2023財年的銷售費用和研發成本,導致該兩年度淨利潤預測調整3%及-3%。目標價相應由9元下調至8元,但維持「跑贏大市」評級,因看到部分新產品將進入市場以推動短期增長。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account